Clinical trial · Interventional
A Feasibility Study On Continuous Adaptive [18f]Fdg-Pet-Guided Radiotherapy For Head and Neck Cancer
A FEASIBILITY STUDY ON CONTINUOUS ADAPTIVE [18F]FDG-PET-GUIDED RADIOTHERAPY FOR HEAD AND NECK CANCER
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Treatment adaptation to biological and anatomical changes occurring during treatment can increase the chance of cure at minimized radiation-induced toxicity in head and neck cancer patients. This trial investigates the feasibility of using repetitive per-treatment \[18F\]FDG-PET acquired during treatment in adaptive \[18F\]FDG-PET-voxel intensity-based intensity-modulated radiotherapy (IMRT) or volumetric-modulated arc therapy (VMAT) for head and neck cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Squamous Cell Carcinoma | Squamous Cell Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| repetitive per-treatment [18F]FDG-PET for treatment adaptation | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- repetitive per-treatment [18F]FDG-PET for treatment adaptation
- interventionNames
- Other: repetitive per-treatment [18F]FDG-PET for treatment adaptation
Primary outcomes (1)
- measure
- To assess volume changes of the targets and organs at risk as detected by repetitive per-treatment [18F]FDG-PET/CT.
- timeFrame
- at time of per-treatment [18F]FDG-PET/CT
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx. * Primary unresectable tumor and/or patients refused surgery. * Stage T1-4; T3-4 N0 or Tany N1-3 for cancer of the glottis. * Multidisciplinary decision of curative radiotherapy or radiochemotherapy. * Karnofsky performance status ≥70%. * Age ≥ 18 years old. * Informed consent obtained, signed and dated before specific protocol procedures. Exclusion Criteria: * Treatment combined with brachytherapy. * Prior irradiation to the head and neck region. * Distant metastases. * Second primary tumors that are not under control * Pregnant or lactating women. * Creatinine clearance (Cockcroft-Gault) ≤ 60 mL/min before treatment. * Allergy to the CT-contrast agents. * Mental condition rendering the patient unable to understand the nature, scope, and possible consequences of the study. * Patient unlikely to comply with protocol, i.e. uncooperative attitude, inability to return for follow-up visits, and unlikely to complete the study.
References
Publications (0)
Data not yet available